<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02989350</url>
  </required_header>
  <id_info>
    <org_study_id>1/2016</org_study_id>
    <nct_id>NCT02989350</nct_id>
  </id_info>
  <brief_title>Efficacy of Lactobacillus Reuteri DSM 17938 for the Treatment of Acute Gastroenteritis in Children</brief_title>
  <official_title>Efficacy of Lactobacillus Reuteri DSM 17938 for the Treatment of Acute Gastroenteritis in Children: Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Szpital im. Św. Jadwigi Śląskiej</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Szpital im. Św. Jadwigi Śląskiej</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute gastroenteritis (AGE) is one of the most common diseases among children. Oral
      rehydration therapy is the key treatment. According to the 2014 guidelines developed by the
      ESPGHAN probiotics may be considered in the management of children with AGE in addition to
      rehydration therapy. Considering that evidence on L reuteri remains limited, the
      investigators aim to assess the efficacy of L reuteri DSM 17938 for the treatment of AGE in
      children. Children vaccinated and not vaccinated against rotavirus will be evaluated
      separately.

      Two independent reports (rotavirus-vaccinated and non-vaccinated children) are planned.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of diarrhea</measure>
    <time_frame>8 days</time_frame>
    <description>(measured in hours) - time until the normalisation of stool consistency according to the Bristol Stool Form Scale(BSF) or Amsterdam Infant Stool Scale (ASF) - (in BSF scale, numbers 1, 2, 3, 4 and 5; in ASF scale, letters B or C), or the time until the normalisation of the number of stools (compared with the period before the onset of diarrhoea).and the presence of normal stools for 48 h.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for intravenous rehydration</measure>
    <time_frame>8 days</time_frame>
    <description>Number of patients in each group requiring intravenous rehydration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of intravenous rehydration</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for hospitalisation of outpatients</measure>
    <time_frame>8 days</time_frame>
    <description>Number of patients enrolled as outpatient requiring hospitalisation - based on medical assesment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of watery stools per day</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vomiting</measure>
    <time_frame>8 days</time_frame>
    <description>Number of participants with vomits and number of vomits per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of diarrhoea (in 48 hours after intervention)</measure>
    <time_frame>48 hours</time_frame>
    <description>Number of patients in which diarrhoea recur after initial recovery in 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of diarrhoea according to Vesikari scale</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of concomitant medications</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Acute Gastroenteritis</condition>
  <arm_group>
    <arm_group_label>Lactobacillus reuteri DSM 17938</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 x 10(8) CFU. Both L reuteri DSM 17938 and placebo will be taken orally, twice daily 5 drops, for consecutive 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo consists of an identical formulation, except active substance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus reuteri DSM 17938</intervention_name>
    <description>Lactobacillus reuteri DSM 17938 vs Placebo</description>
    <arm_group_label>Lactobacillus reuteri DSM 17938</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Lactobacillus reuteri DSM 17938 vs Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Acute gastroenteritis (AGE) defined as a change in stool consistency to loose or
             liquid form (according to the Bristol Stool Form (BSF) scale or in the case of
             infants, the Amsterdam Stool Form (ASF) scale) and/or an increase in the frequency of
             evacuations (typically ≥3 in 24 h), lasting for no longer than 5 days.

          2. Age: older than 1 month and younger than 60 months.

          3. A caregiver must provide written informed consent.

        Exclusion Criteria:

          1. Use of antibiotics within two weeks prior to enrolment.

          2. Use of gelatine tannate, diosmectite, probiotics, racecadotril, or zinc (including
             zinc containing ORS) within a week prior to enrolment (a single dose is allowed).

          3. Breast feeding (&gt;50%)

          4. Chronic diarrhoeal gastrointestinal disease (e.g., inflammatory bowel disease, cystic
             fibrosis, coeliac disease, food allergy)

          5. Immunodeficiency

          6. Malnutrition (weight/height/length under 3rd percentile) (WHO Child Growth Standards
             will be used)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>60 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henryk Szymański, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Szpital im.Świętej Jadwigi Śląskiej, Trzebnica, Poland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henryk Szymański, MD PhD</last_name>
    <phone>0048604467073</phone>
    <email>henryk.t.szymanski@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Szpiatal im.Świętej Jadwigi Śląskiej</name>
      <address>
        <city>Trzebnica</city>
        <zip>55-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henryk Szymański, MD PhD</last_name>
      <phone>0048604467073</phone>
      <email>henryk.t.szymanski@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>http://www.researchprotocols.org/2017/8/e164/</url>
    <description>published protocol</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2016</study_first_submitted>
  <study_first_submitted_qc>December 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2016</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Szpital im. Św. Jadwigi Śląskiej</investigator_affiliation>
    <investigator_full_name>Henryk Szymański</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroenteritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

